Advertisement

Special Considerations for Long-Term Survivors After Hematopoietic Stem Cell Transplantation

Chapter

Abstract

Significant decrease in early mortality after hematopoietic stem cell transplantation (HCT) has resulted in an increasing number of long-term survivors. Long-term transplant survivors are at risk for developing late complications such as chronic graft-versus-host disease (GVHD) and late infections. Late infections with bacteria, viruses, fungi, and other organisms are most common in patients with chronic GVHD and those who received T depleted or cord blood transplants. Evidence based data to guide specific recommendations for duration of infectious prophylaxis beyond 100 days after HCT is limited, and clinical practice is variable and based on type of transplant, GVHD status, immunosuppression therapy, viral serology status pre-transplant of patients and donors, diagnosis at transplant, prior treatment with certain chemotherapeutic agents, and prior history of infections. Special consideration for HCT recipients beyond 100 days after transplant, including recommendations for anti-microbial prophylaxis, based on recent international guidelines, recent literature review, and standard practice at the Fred Hutchinson Cancer Research Center (FHCRC), is discussed in this chapter.

Keywords

Chronic graft-versus-host disease (cGVHD) Varicella zoster virus (VZV) Cytomegalovirus (CMV) Pneumocystis jiroveci pneumonia (PJP) Toxoplasma Encapsulated bacteria 

References

  1. 1.
    Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363(22):2091–101.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Socie G, Stone JV, Wingard JR, Weisdorf D, Henslee-Downey PJ, Bredeson C, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med. 1999;341(1):14–21.PubMedCrossRefGoogle Scholar
  3. 3.
    Bhatia S, Francisco L, Carter A, Sun CL, Baker KS, Gurney JG, et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood. 2007;110(10):3784–92.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Martin PJ, Counts Jr GW, Appelbaum FR, Lee SJ, Sanders JE, Deeg HJ, et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol. 2010;28(6):1011–6.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    van Burik JA, Weisdorf DJ. Infections in recipients of blood and marrow transplantation. Hematol Oncol Clin North Am. 1999;13(5):1065–89. viii.PubMedCrossRefGoogle Scholar
  6. 6.
    Sable CA, Donowitz GR. Infections in bone marrow transplant recipients. Clin Infect Dis. 1994;18(3):273–81. quiz 82–4.PubMedCrossRefGoogle Scholar
  7. 7.
    Al-Mansour Z, Ramanathan M. Post-autologous (ASCT) stem cell transplant therapy in multiple myeloma. Adv Hematol. 2014;2014:652395.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Vincent Rajkumar S. Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management. Am J Hematol. 2014;89(10):999–1009.PubMedGoogle Scholar
  9. 9.
    McCarthy PL, Palumbo A. Maintenance therapy for multiple myeloma. Hematol Oncol Clin North Am. 2014;28(5):839–59.PubMedCrossRefGoogle Scholar
  10. 10.
    Blimark C, Holmberg E, Mellqvist UH, Landgren O, Bjorkholm M, Hultcrantz M, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100(1):107–13.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Morrison VA. Immunosuppression associated with novel chemotherapy agents and monoclonal antibodies. Clin Infect Dis. 2014;59 Suppl 5:S360–4.PubMedCrossRefGoogle Scholar
  12. 12.
    Gao M, Gao L, Yang G, Tao Y, Tompkins VS, Wu X, et al. Lenalidomide after stem-cell transplantation for multiple myeloma: a meta-analysis of randomized controlled trials. Int J Clin Exp Pathol. 2014;7(6):3073–80.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15(10):1143–238.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Storek J, Geddes M, Khan F, Huard B, Helg C, Chalandon Y, et al. Reconstitution of the immune system after hematopoietic stem cell transplantation in humans. Semin Immunopathol. 2008;30(4):425–37.PubMedCrossRefGoogle Scholar
  15. 15.
    Mackall CL, Fleisher TA, Brown MR, Magrath IT, Shad AT, Horowitz ME, et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood. 1994;84(7):2221–8.PubMedGoogle Scholar
  16. 16.
    Storek J, Witherspoon RP, Storb R. T cell reconstitution after bone marrow transplantation into adult patients does not resemble T cell development in early life. Bone Marrow Transplant. 1995;16(3):413–25.PubMedGoogle Scholar
  17. 17.
    Toubert A, Glauzy S, Douay C, Clave E. Thymus and immune reconstitution after allogeneic hematopoietic stem cell transplantation in humans: never say never again. Tissue Antigens. 2012;79(2):83–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Fujimaki K, Maruta A, Yoshida M, Kodama F, Matsuzaki M, Fujisawa S, et al. Immune reconstitution assessed during five years after allogeneic bone marrow transplantation. Bone Marrow Transplant. 2001;27(12):1275–81.PubMedCrossRefGoogle Scholar
  19. 19.
    Crooks GM, Weinberg K, Mackall C. Immune reconstitution: from stem cells to lymphocytes. Biol Blood Marrow Transplant. 2006;12(1 Suppl 1):42–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Storek J, Ferrara S, Ku N, Giorgi JV, Champlin RE, Saxon A. B cell reconstitution after human bone marrow transplantation: recapitulation of ontogeny? Bone Marrow Transplant. 1993;12(4):387–98.PubMedGoogle Scholar
  21. 21.
    Gerritsen EJ, Van Tol MJ, Van 't Veer MB, Wels JM, Khouw IM, Touw CR, et al. Clonal dysregulation of the antibody response to tetanus-toxoid after bone marrow transplantation. Blood. 1994;84(12):4374–82.PubMedGoogle Scholar
  22. 22.
    Klyuchnikov E, Asenova S, Kern W, Kilinc G, Ayuk F, Wiedemann B, et al. Post-transplant immune reconstitution after unrelated allogeneic stem cell transplant in patients with acute myeloid leukemia. Leuk Lymphoma. 2010;51(8):1450–63.PubMedCrossRefGoogle Scholar
  23. 23.
    Storek J, Dawson MA, Storer B, Stevens-Ayers T, Maloney DG, Marr KA, et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood. 2001;97(11):3380–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Ottinger HD, Beelen DW, Scheulen B, Schaefer UW, Grosse-Wilde H. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood. 1996;88(7):2775–9.PubMedGoogle Scholar
  25. 25.
    Flowers ME, Inamoto Y, Carpenter PA, Lee SJ, Kiem HP, Petersdorf EW, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011;117(11):3214–9.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Stewart BL, Storer B, Storek J, Deeg HJ, Storb R, Hansen JA, et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood. 2004;104(12):3501–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Akpek G, Lee SJ, Flowers ME, Pavletic SZ, Arora M, Lee S, et al. Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study. Blood. 2003;102(3):802–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9(4):215–33.PubMedCrossRefGoogle Scholar
  29. 29.
    Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945–56.PubMedCrossRefGoogle Scholar
  30. 30.
    Abrahamsen IW, Somme S, Heldal D, Egeland T, Kvale D, Tjonnfjord GE. Immune reconstitution after allogeneic stem cell transplantation: the impact of stem cell source and graft-versus-host disease. Haematologica. 2005;90(1):86–93.PubMedGoogle Scholar
  31. 31.
    Shono Y, Shiratori S, Kosugi-Kanaya M, Ueha S, Sugita J, Shigematsu A, et al. Bone marrow graft-versus-host disease: evaluation of its clinical impact on disrupted hematopoiesis after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20(4):495–500.PubMedCrossRefGoogle Scholar
  32. 32.
    Peggs KS. Immune reconstitution following stem cell transplantation. Leuk Lymphoma. 2004;45(6):1093–101.PubMedCrossRefGoogle Scholar
  33. 33.
    Shono Y, Ueha S, Wang Y, Abe J, Kurachi M, Matsuno Y, et al. Bone marrow graft-versus-host disease: early destruction of hematopoietic niche after MHC-mismatched hematopoietic stem cell transplantation. Blood. 2010;115(26):5401–11.PubMedCrossRefGoogle Scholar
  34. 34.
    Baker MB, Riley RL, Podack ER, Levy RB. Graft-versus-host-disease-associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cell-mediated Fas-ligand function, but not perforin function. Proc Natl Acad Sci U S A. 1997;94(4):1366–71.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Flowers ME, Storer B, Carpenter P, Rezvani AR, Vigorito AC, Campregher PV, et al. Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2008;14(12):1380–4.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Inamoto Y, Flowers ME, Sandmaier BM, Aki SZ, Carpenter PA, Lee SJ, et al. Failure-free survival after initial systemic treatment of chronic graft-versus-host disease. Blood. 2014;124(8):1363–71.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Vigorito AC, Campregher PV, Storer BE, Carpenter PA, Moravec CK, Kiem HP, et al. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood. 2009;114(3):702–8.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Fauci AS. Immunosuppressive and anti-inflammatory effects of glucocorticoids. Monogr Endocrinol. 1979;12:449–65.PubMedCrossRefGoogle Scholar
  39. 39.
    Cupps TR, Fauci AS. Corticosteroid-mediated immunoregulation in man. Immunol Rev. 1982;65:133–55.PubMedCrossRefGoogle Scholar
  40. 40.
    Haczku A, Alexander A, Brown P, Assoufi B, Li B, Kay AB, et al. The effect of dexamethasone, cyclosporine, and rapamycin on T-lymphocyte proliferation in vitro: comparison of cells from patients with glucocorticoid-sensitive and glucocorticoid-resistant chronic asthma. J Allergy Clin Immunol. 1994;93(2):510–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Perreault C, Giasson M, Gyger M, Belanger R, David M, Bonny Y, et al. Serum immunoglobulin levels following allogeneic bone marrow transplantation. Blut. 1985;51(3):137–42.PubMedCrossRefGoogle Scholar
  42. 42.
    Noel DR, Witherspoon RP, Storb R, Atkinson K, Doney K, Mickelson EM, et al. Does graft-versus-host disease influence the tempo of immunologic recovery after allogeneic human marrow transplantation? An observation on 56 long-term survivors. Blood. 1978;51(6):1087–105.PubMedGoogle Scholar
  43. 43.
    Fauci AS, Dale DC, Balow JE. Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med. 1976;84(3):304–15.PubMedCrossRefGoogle Scholar
  44. 44.
    Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med. 1993;119(12):1198–208.PubMedCrossRefGoogle Scholar
  45. 45.
    Cox G. Glucocorticoid treatment inhibits apoptosis in human neutrophils. Separation of survival and activation outcomes. J Immunol. 1995;154(9):4719–25.PubMedGoogle Scholar
  46. 46.
    Nagase H, Miyamasu M, Yamaguchi M, Kawasaki H, Ohta K, Yamamoto K, et al. Glucocorticoids preferentially upregulate functional CXCR4 expression in eosinophils. J Allergy Clin Immunol. 2000;106(6):1132–9.PubMedCrossRefGoogle Scholar
  47. 47.
    Schleimer RP, Freeland HS, Peters SP, Brown KE, Derse CP. An assessment of the effects of glucocorticoids on degranulation, chemotaxis, binding to vascular endothelium and formation of leukotriene B4 by purified human neutrophils. J Pharmacol Exp Ther. 1989;250(2):598–605.PubMedGoogle Scholar
  48. 48.
    Jones CJ, Morris KJ, Jayson MI. Prednisolone inhibits phagocytosis by polymorphonuclear leucocytes via steroid receptor mediated events. Ann Rheum Dis. 1983;42(1):56–62.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Rinehart JJ, Sagone AL, Balcerzak SP, Ackerman GA, LoBuglio AF. Effects of corticosteroid therapy on human monocyte function. N Engl J Med. 1975;292(5):236–41.PubMedCrossRefGoogle Scholar
  50. 50.
    Komanduri KV, St John LS, de Lima M, McMannis J, Rosinski S, McNiece I, et al. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood. 2007;110(13):4543–51.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Chalmers IM, Janossy G, Contreras M, Navarrete C. Intracellular cytokine profile of cord and adult blood lymphocytes. Blood. 1998;92(1):11–8.PubMedGoogle Scholar
  52. 52.
    Risdon G, Gaddy J, Stehman FB, Broxmeyer HE. Proliferative and cytotoxic responses of human cord blood T lymphocytes following allogeneic stimulation. Cell Immunol. 1994;154(1):14–24.PubMedCrossRefGoogle Scholar
  53. 53.
    Brown JA, Boussiotis VA. Umbilical cord blood transplantation: basic biology and clinical challenges to immune reconstitution. Clin Immunol. 2008;127(3):286–97.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Politikos I, Boussiotis VA. The role of the thymus in T-cell immune reconstitution after umbilical cord blood transplantation. Blood. 2014;124(22):3201–11.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Verfuerth S, Peggs K, Vyas P, Barnett L, O’Reilly RJ, Mackinnon S. Longitudinal monitoring of immune reconstitution by CDR3 size spectratyping after T-cell-depleted allogeneic bone marrow transplant and the effect of donor lymphocyte infusions on T-cell repertoire. Blood. 2000;95(12):3990–5.PubMedGoogle Scholar
  56. 56.
    van Burik JA, Carter SL, Freifeld AG, High KP, Godder KT, Papanicolaou GA, et al. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease. Biol Blood Marrow Transplant. 2007;13(12):1487–98.PubMedCrossRefGoogle Scholar
  57. 57.
    Barker JN, Hough RE, van Burik JA, DeFor TE, MacMillan ML, O’Brien MR, et al. Serious infections after unrelated donor transplantation in 136 children: impact of stem cell source. Biol Blood Marrow Transplant. 2005;11(5):362–70.PubMedCrossRefGoogle Scholar
  58. 58.
    Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10(9):855–64.PubMedCrossRefGoogle Scholar
  59. 59.
    Lang P, Greil J, Bader P, Handgretinger R, Klingebiel T, Schumm M, et al. Long-term outcome after haploidentical stem cell transplantation in children. Blood Cells Mol Dis. 2004;33(3):281–7.PubMedCrossRefGoogle Scholar
  60. 60.
    Mulanovich VE, Jiang Y, de Lima M, Shpall EJ, Champlin RE, Ciurea SO. Infectious complications in cord blood and T-cell depleted haploidentical stem cell transplantation. Am J Blood Res. 2011;1(1):98–105.PubMedPubMedCentralGoogle Scholar
  61. 61.
    Chang YJ, Zhao XY, Huang XJ. Immune reconstitution after haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20(4):440–9.PubMedCrossRefGoogle Scholar
  62. 62.
    Crocchiolo R, Bramanti S, Vai A, Sarina B, Mineri R, Casari E, et al. Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis. Transpl Infect Dis. 2015;17(2):242–9.PubMedCrossRefGoogle Scholar
  63. 63.
    Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis. 2009;49(8):1211–25.PubMedCrossRefGoogle Scholar
  64. 64.
    Basler M, Lauer C, Beck U, Groettrup M. The proteasome inhibitor bortezomib enhances the susceptibility to viral infection. J Immunol. 2009;183(10):6145–50.PubMedCrossRefGoogle Scholar
  65. 65.
    Kim SJ, Kim K, Kim BS, Lee HJ, Kim H, Lee NR, et al. Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma. Clin Lymphoma Myeloma. 2008;8(4):237–40.PubMedCrossRefGoogle Scholar
  66. 66.
    Marchesi F, Mengarelli A, Giannotti F, Tendas A, Anaclerico B, Porrini R, et al. High incidence of post-transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib-based regimens: a survey from the Rome transplant network. Transpl Infect Dis. 2014;16(1):158–64.PubMedCrossRefGoogle Scholar
  67. 67.
    Marr KA. Delayed opportunistic infections in hematopoietic stem cell transplantation patients: a surmountable challenge. Hematology Am Soc Hematol Educ Program. 2012;2012:265–70.PubMedPubMedCentralGoogle Scholar
  68. 68.
    Carpenter PA, Kitko CL, Elad S, Flowers ME, Gea-Banacloche JC, Halter JP, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant. 2015;21(7):1167–87.PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Srinivasan A, Wang C, Srivastava DK, Burnette K, Shenep JL, Leung W, et al. Timeline, epidemiology, and risk factors for bacterial, fungal, and viral infections in children and adolescents after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19(1):94–101.PubMedCrossRefGoogle Scholar
  70. 70.
    Gudiol C, Garcia-Vidal C, Arnan M, Sanchez-Ortega I, Patino B, Duarte R, et al. Etiology, clinical features and outcomes of pre-engraftment and post-engraftment bloodstream infection in hematopoietic SCT recipients. Bone Marrow Transplant. 2014;49(6):824–30.PubMedCrossRefGoogle Scholar
  71. 71.
    Benjamin Jr DK, Miller WC, Bayliff S, Martel L, Alexander KA, Martin PL. Infections diagnosed in the first year after pediatric stem cell transplantation. Pediatr Infect Dis J. 2002;21(3):227–34.PubMedCrossRefGoogle Scholar
  72. 72.
    Rizzo JD, Wingard JR, Tichelli A, Lee SJ, Van Lint MT, Burns LJ, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2006;12(2):138–51.Google Scholar
  73. 73.
    Krajicek BJ, Thomas Jr CF, Limper AH. Pneumocystis pneumonia: current concepts in pathogenesis, diagnosis, and treatment. Clin Chest Med. 2009;30(2):265–78. vi.PubMedCrossRefGoogle Scholar
  74. 74.
    Muto T, Takeuchi M, Kawaguchi T, Tanaka S, Tsukamoto S, Sakai S, et al. Low-dose trimethoprim-sulfamethoxazole for Pneumocystis jiroveci pneumonia prophylaxis after allogeneic hematopoietic SCT. Bone Marrow Transplant. 2011;46(12):1573–5.PubMedCrossRefGoogle Scholar
  75. 75.
    Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev. 2004;17(4):770–82, table of contents.Google Scholar
  76. 76.
    Vasconcelles MJ, Bernardo MV, King C, Weller EA, Antin JH. Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections. Biol Blood Marrow Transplant. 2000;6(1):35–43.PubMedCrossRefGoogle Scholar
  77. 77.
    Marras TK, Sanders K, Lipton JH, Messner HA, Conly J, Chan CK. Aerosolized pentamidine prophylaxis for Pneumocystis carinii pneumonia after allogeneic marrow transplantation. Transpl Infect Dis. 2002;4(2):66–74.PubMedCrossRefGoogle Scholar
  78. 78.
    Martino R, Maertens J, Bretagne S, Rovira M, Deconinck E, Ullmann AJ, et al. Toxoplasmosis after hematopoietic stem cell transplantation. Clin Infect Dis. 2000;31(5):1188–95.PubMedCrossRefGoogle Scholar
  79. 79.
    Busemann C, Ribback S, Zimmermann K, Sailer V, Kiefer T, Schmidt CA, et al. Toxoplasmosis after allogeneic stem cell transplantation—a single centre experience. Ann Hematol. 2012;91(7):1081–9.PubMedCrossRefGoogle Scholar
  80. 80.
    Slavin MA, Meyers JD, Remington JS, Hackman RC. Toxoplasma gondii infection in marrow transplant recipients: a 20 year experience. Bone Marrow Transplant. 1994;13(5):549–57.PubMedGoogle Scholar
  81. 81.
    Mele A, Paterson PJ, Prentice HG, Leoni P, Kibbler CC. Toxoplasmosis in bone marrow transplantation: a report of two cases and systematic review of the literature. Bone Marrow Transplant. 2002;29(8):691–8.PubMedCrossRefGoogle Scholar
  82. 82.
    Mendorf A, Klyuchnikov E, Langebrake C, Rohde H, Ayuk F, Regier M, et al. Atovaquone for prophylaxis of toxoplasmosis after allogeneic hematopoietic stem cell transplantation. Acta Haematol. 2015;134(3):146–54.PubMedCrossRefGoogle Scholar
  83. 83.
    Derouin F, Piketty C, Chastang C, Chau F, Rouveix B, Pocidalo JJ. Anti-Toxoplasma effects of dapsone alone and combined with pyrimethamine. Antimicrob Agents Chemother. 1991;35(2):252–5.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Payen MC, De Wit S, Sommereijns B, Clumeck N. A controlled trial of dapsone versus pyrimethamine-sulfadoxine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmosis in patients with AIDS. Biomed Pharmacother. 1997;51(10):439–45.PubMedCrossRefGoogle Scholar
  85. 85.
    Podzamczer D, Salazar A, Jimenez J, Consiglio E, Santin M, Casanova A, et al. Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV. Ann Intern Med. 1995;122(10):755–61.PubMedCrossRefGoogle Scholar
  86. 86.
    Foot AB, Garin YJ, Ribaud P, Devergie A, Derouin F, Gluckman E. Prophylaxis of toxoplasmosis infection with pyrimethamine/sulfadoxine (Fansidar) in bone marrow transplant recipients. Bone Marrow Transplant. 1994;14(2):241–5.PubMedGoogle Scholar
  87. 87.
    Steer CB, Szer J, Sasadeusz J, Matthews JP, Beresford JA, Grigg A. Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir. Bone Marrow Transplant. 2000;25(6):657–64.PubMedCrossRefGoogle Scholar
  88. 88.
    Erard V, Guthrie KA, Varley C, Heugel J, Wald A, Flowers ME, et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood. 2007;110(8):3071–7.PubMedCrossRefGoogle Scholar
  89. 89.
    Boeckh M. Prevention of VZV infection in immunosuppressed patients using antiviral agents. Herpes. 2006;13(3):60–5.PubMedGoogle Scholar
  90. 90.
    Kanda Y, Mineishi S, Saito T, Saito A, Yamada S, Ohnishi M, et al. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;28(7):689–92.PubMedCrossRefGoogle Scholar
  91. 91.
    Asano-Mori Y, Kanda Y, Oshima K, Kako S, Shinohara A, Nakasone H, et al. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2008;83(6):472–6.PubMedCrossRefGoogle Scholar
  92. 92.
    Kawamura K, Wada H, Yamasaki R, Ishihara Y, Sakamoto K, Ashizawa M, et al. Prophylactic role of long-term ultra-low-dose acyclovir for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. Int J Infect Dis. 2014;19:26–32.PubMedCrossRefGoogle Scholar
  93. 93.
    George B, Pati N, Gilroy N, Ratnamohan M, Huang G, Kerridge I, et al. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy. Transpl Infect Dis. 2010;12(4):322–9.PubMedCrossRefGoogle Scholar
  94. 94.
    Boeckh M, Leisenring W, Riddell SR, Bowden RA, Huang ML, Myerson D, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood. 2003;101(2):407–14.PubMedCrossRefGoogle Scholar
  95. 95.
    Reddy SM, Winston DJ, Territo MC, Schiller GJ. CMV central nervous system disease in stem-cell transplant recipients: an increasing complication of drug-resistant CMV infection and protracted immunodeficiency. Bone Marrow Transplant. 2010;45(6):979–84.PubMedCrossRefGoogle Scholar
  96. 96.
    Jeon S, Lee WK, Lee Y, Lee DG, Lee JW. Risk factors for cytomegalovirus retinitis in patients with cytomegalovirus viremia after hematopoietic stem cell transplantation. Ophthalmology. 2012;119(9):1892–8.PubMedCrossRefGoogle Scholar
  97. 97.
    Torok-Storb B, Boeckh M, Hoy C, Leisenring W, Myerson D, Gooley T. Association of specific cytomegalovirus genotypes with death from myelosuppression after marrow transplantation. Blood. 1997;90(5):2097–102.PubMedGoogle Scholar
  98. 98.
    Ljungman P. The role of cytomegalovirus serostatus on outcome of hematopoietic stem cell transplantation. Curr Opin Hematol. 2014;21(6):466–9.PubMedCrossRefGoogle Scholar
  99. 99.
    Schmidt-Hieber M, Labopin M, Beelen D, Volin L, Ehninger G, Finke J, et al. CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. Blood. 2013;122(19):3359–64.PubMedCrossRefGoogle Scholar
  100. 100.
    Milano F, Pergam SA, Xie H, Leisenring WM, Gutman JA, Riffkin I, et al. Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients. Blood. 2011;118(20):5689–96.PubMedPubMedCentralCrossRefGoogle Scholar
  101. 101.
    Mikulska M, Raiola AM, Bruzzi P, Varaldo R, Annunziata S, Lamparelli T, et al. CMV infection after transplant from cord blood compared to other alternative donors: the importance of donor-negative CMV serostatus. Biol Blood Marrow Transplant. 2012;18(1):92–9.PubMedCrossRefGoogle Scholar
  102. 102.
    Dahi PB, Perales MA, Devlin SM, Olson A, Lubin M, Gonzales AM, et al. Incidence, nature and mortality of cytomegalovirus infection after double-unit cord blood transplant. Leuk Lymphoma. 2015;56(6):1799–805.PubMedCrossRefGoogle Scholar
  103. 103.
    Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant. 2003;9(9):543–58.PubMedCrossRefGoogle Scholar
  104. 104.
    Walker CM, van Burik JA, De For TE, Weisdorf DJ. Cytomegalovirus infection after allogeneic transplantation: comparison of cord blood with peripheral blood and marrow graft sources. Biol Blood Marrow Transplant. 2007;13(9):1106–15.PubMedCrossRefGoogle Scholar
  105. 105.
    Tomonari A, Takahashi S, Ooi J, Tsukada N, Konuma T, Kato S, et al. Impact of cytomegalovirus serostatus on outcome of unrelated cord blood transplantation for adults: a single-institute experience in Japan. Eur J Haematol. 2008;80(3):251–7.PubMedCrossRefGoogle Scholar
  106. 106.
    Boeckh M, Nichols WG, Chemaly RF, Papanicolaou GA, Wingard JR, Xie H, et al. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial. Ann Intern Med. 2015;162(1):1–10.PubMedPubMedCentralCrossRefGoogle Scholar
  107. 107.
    Ljungman P, de La Camara R, Milpied N, Volin L, Russell CA, Crisp A, et al. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood. 2002;99(8):3050–6.PubMedCrossRefGoogle Scholar
  108. 108.
    Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med. 1993;118(3):173–8.PubMedCrossRefGoogle Scholar
  109. 109.
    Green ML, Leisenring W, Stachel D, Pergam SA, Sandmaier BM, Wald A, et al. Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18(11):1687–99.PubMedPubMedCentralCrossRefGoogle Scholar
  110. 110.
    Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp 65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood. 1996;88(10):4063–71.PubMedGoogle Scholar
  111. 111.
    Erard V, Chien JW, Kim HW, Nichols WG, Flowers ME, Martin PJ, et al. Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: the role of community respiratory viruses. J Infect Dis. 2006;193(12):1619–25.PubMedCrossRefGoogle Scholar
  112. 112.
    Chemaly RF, Ghosh S, Bodey GP, Rohatgi N, Safdar A, Keating MJ, et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine. 2006;85(5):278–87.PubMedCrossRefGoogle Scholar
  113. 113.
    Peck AJ, Englund JA, Kuypers J, Guthrie KA, Corey L, Morrow R, et al. Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection. Blood. 2007;110(5):1681–8.PubMedPubMedCentralCrossRefGoogle Scholar
  114. 114.
    Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis. 2004;39(9):1300–6.PubMedCrossRefGoogle Scholar
  115. 115.
    Seo S, Xie H, Karron RA, Thumar B, Englund JA, Leisenring WM, et al. Parainfluenza virus type 3 Ab in allogeneic hematopoietic cell transplant recipients: factors influencing post-transplant Ab titers and associated outcomes. Bone Marrow Transplant. 2014;49(9):1205–11.PubMedPubMedCentralCrossRefGoogle Scholar
  116. 116.
    Seo S, Xie H, Campbell AP, Kuypers JM, Leisenring WM, Englund JA, et al. Parainfluenza virus lower respiratory tract disease after hematopoietic cell transplant: viral detection in the lung predicts outcome. Clin Infect Dis. 2014;58(10):1357–68.PubMedPubMedCentralCrossRefGoogle Scholar
  117. 117.
    Kim YJ, Guthrie KA, Waghmare A, Walsh EE, Falsey AR, Kuypers J, et al. Respiratory syncytial virus in hematopoietic cell transplant recipients: factors determining progression to lower respiratory tract disease. J Infect Dis. 2014;209(8):1195–204.PubMedCrossRefGoogle Scholar
  118. 118.
    Ljungman P, Cordonnier C, Einsele H, Englund J, Machado CM, Storek J, et al. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant. 2009;44(8):521–6.PubMedCrossRefGoogle Scholar
  119. 119.
    Robenshtok E, Gafter-Gvili A, Goldberg E, Weinberger M, Yeshurun M, Leibovici L, et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol. 2007;25(34):5471–89.PubMedCrossRefGoogle Scholar
  120. 120.
    Grow WB, Moreb JS, Roque D, Manion K, Leather H, Reddy V, et al. Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant. 2002;29(1):15–9.PubMedCrossRefGoogle Scholar
  121. 121.
    Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002;100(13):4358–66.PubMedCrossRefGoogle Scholar
  122. 122.
    Jantunen E, Ruutu P, Niskanen L, Volin L, Parkkali T, Koukila-Kahkola P, et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant. 1997;19(8):801–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Open Access This chapter is distributed under the terms of the Creative Commons Attribution Noncommercial License, which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Authors and Affiliations

  1. 1.Fred Hutchinson Cancer Research Center, University of WashingtonSeattleUSA

Personalised recommendations